4.8 Article

Polymerase-mediated ultramutagenesis in mice produces diverse cancers with high mutational load

期刊

JOURNAL OF CLINICAL INVESTIGATION
卷 128, 期 9, 页码 4179-4191

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI122095

关键词

-

资金

  1. Vernie A. Stembridge MD fund
  2. NIH, National Cancer Institute (NCI) [R01HD086093, R01CA211339, R01CA164346, R01CA200703]
  3. Cancer Prevention and Research Institute of Texas [RP150596]

向作者/读者索取更多资源

Mutations underlie all cancers, and their identification and study are the foundation of cancer biology. We describe what we believe to be a novel approach to mutagenesis and cancer studies based on the DNA polymerase epsilon (POLE) ultramutator phenotype recently described in human cancers, in which a single amino acid substitution (most commonly P286R) in the proofreading domain results in error-prone DNA replication. We engineered a conditional Pole(P286R) allele in mice. Pole(P286R/+) embryonic fibroblasts exhibited a striking mutator phenotype and immortalized more efficiently. Pole(P286R/+) mice were born at Mendelian ratios but rapidly developed lethal cancers of diverse lineages, yielding the most cancer-prone monoallelic model described to date, to our knowledge. Comprehensive whole-genome sequencing analyses showed that the cancers were driven by high base substitution rates in the range of human cancers, overcoming a major limitation of previous murine cancer models. These data establish polymerase-mediated ultramutagenesis as an efficient in vivo approach for the generation of diverse animal cancer models that recapitulate the high mutational loads inherent to human cancers.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据